The detailed interactions in Supplementary Fig. S4D highlight CCL20 and TNFRSF25 as critical players linked to immune/inflammatory pathways, underscore the therapeutic potential of upregulated genes in H. pylori–associated gastric cancer, and provide a basis for both drug repurposing and novel drug development, advancing strategies for targeted treatment. This evidence concerns the gene TNFRSF25 and gastric cancer.